What is the etiology of follicular lymphadenitis and how should it be managed?

Management of Follicular Lymphadenitis

You are likely asking about either follicular lymphoma (a malignant B-cell neoplasm) or infectious lymphadenitis with follicular hyperplasia—these are completely different entities requiring distinct approaches.

If This is Follicular Lymphoma (Malignant)

Etiology

Follicular lymphoma is a B-cell neoplasm characterized by malignant transformation of germinal center B cells, representing the second most common lymphoid malignancy in Western countries with an incidence of 5/100,000 1. The exact cause remains unclear, though the disease has shown increasing incidence from 2-3/100,000 in the 1950s to current rates without clear explanation 1.

Diagnosis

• Excisional lymph node biopsy is mandatory—fine-needle aspiration is insufficient 1
• Core biopsies only acceptable when easily accessible nodes are unavailable (e.g., retroperitoneal) 1
• Histological grading: grades 1,2, and 3A are indolent; grade 3B is aggressive and treated as such 1
• PET-CT is required for staging and to confirm localized stage I/II disease before radiotherapy 1, 2
• Bone marrow biopsy (≥20 mm), complete blood count, LDH, β2-microglobulin, immunoglobulin levels, and screening for HIV/HBV/HCV 1

Management Algorithm

For Localized Disease (Stage I/II):

• Involved-site radiotherapy (ISRT) is the treatment of choice 2

For Advanced-Stage Disease with Low Tumor Burden:

• Watch-and-wait approach is appropriate for asymptomatic patients 2
• Rituximab monotherapy is acceptable alternative 2

For Advanced-Stage Disease with High Tumor Burden:

• Immunochemotherapy with anti-CD20 antibodies (rituximab or obinutuzumab) combined with CHOP, CVP, or bendamustine, followed by maintenance therapy 2

For Relapsed/Refractory Disease After ≥2 Prior Therapies:

• CD19-directed CAR T-cell therapies (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) 3
• CD3 x CD20 bispecific antibodies (mosunetuzumab, epcoritamab) 3
• Tafasitamab + lenalidomide + rituximab demonstrated significantly improved progression-free survival in the phase III inMIND study 3
• Zanubrutinib + obinutuzumab 3

Critical Prognostic Factor

Progression of disease within 24 months of initial diagnosis indicates poor survival and should prompt consideration of novel treatment approaches 3.

---

If This is Infectious Lymphadenitis (Non-Malignant)

Etiology

Bacterial causes dominate acute suppurative lymphadenitis:

• Staphylococcus aureus is the most common organism (94% of positive cultures in pediatric series) 4, 5, 6
• Streptococcus pyogenes (though may be reduced by pre-hospital beta-lactam use) 4, 5
• Bartonella henselae (cat scratch disease) is now the most frequently identified infectious agent overall since PCR became available 7
• Mycobacterium avium subspecies hominissuis in children 7, 6
• Viral infections (often preceding bacterial superinfection) 7, 8

Clinical Presentation

• Neck swelling/erythema (99%) 4
• Fever (73%) 4
• Neck pain (30%) and torticollis (9%) 4
• 34% have preceding upper respiratory tract infection 4
• Nodes >2 cm, hard, or matted suggest malignancy or granulomatous disease 8

Management Algorithm

Initial Approach:

1. If lymphadenopathy persists >4 weeks or accompanied by fever, night sweats, or unintentional weight loss: obtain imaging, complete blood count, C-reactive protein, ESR, tuberculosis testing 8
2. Epitrochlear or supraclavicular nodes warrant immediate investigation for malignancy 8

Antibiotic Selection:

• Empiric therapy targets S. aureus and S. pyogenes 5
• Resistance patterns favor vancomycin, cotrimoxazole, or oxacillin (6% resistance each) over clindamycin (12% resistance) despite clindamycin being commonly used 4
• Avoid corticosteroids—they mask histologic diagnosis of lymphoma 8

Surgical Intervention:

• Aspiration or incision/drainage indicated for suppurative disease not responding to antibiotics 4, 5
• Complete surgical excision is decisive for mycobacterial lymphadenitis 6
• Mean hospitalization duration: 6 days 4

If Empiric Antibiotics Fail:

• Trigger diagnostic re-evaluation with culture, PCR, and biopsy (fine-needle aspiration, core needle, or excisional) 7, 8, 5
• PCR has revolutionized diagnosis by identifying previously unrecognized organisms 7

Critical Pitfall

Do not assume all lymphadenitis is infectious—failure to respond to empiric antibiotics within 48-72 hours necessitates consideration of alternative diagnoses including malignancy, particularly in children with hard, matted nodes >2 cm 8, 5.